GlassScriptPhysician profile
Andrew J Kirsch
NPI 1336243898
$320,221.24
in general payments reported to CMS, 2019-2025
30 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Pediatric Urology providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,117 · 2020: $42K · 2021: $28K · 2022: $59K · 2023: $51K · 2024: $74K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $94K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Grant: $10K · Travel and Lodging: $9,154 · Food and Beverage: $5,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $93,823.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,967.50 |
| Grant | $10,000.00 |
| Travel and Lodging | $9,153.52 |
| Food and Beverage | $5,479.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $185,689.96 | 2019-2023 | |
| Teleflex LLC | $130,837.94 | 2024-2025 | Deflux, Deflux Metal Needle |
| Intuitive Surgical, INC. | $985.00 | 2019-2022 | |
| Boston Scientific Corporation | $833.52 | 2021-2025 | Lithovue, Spaceoar System, Ams 700 |
| Conmed Corporation | $233.88 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $227.38 | 2023-2025 | Orgovyx |
| Accord Healthcare, INC. | $206.46 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.41 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $168.00 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| C. R. Bard, INC. & Subsidiaries | $137.72 | 2023-2025 | Magic3 Go Intermittent Urinary Catheter |
| Myovant Sciences INC. | $115.21 | 2021 | |
| Blue Earth Diagnostics | $70.78 | 2022 | |
| Novo Nordisk INC | $68.96 | 2024 | |
| Coloplast Corp | $65.90 | 2023-2025 | Speedicath |
| Urogen Pharma, INC. | $52.09 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bracco Diagnostics INC. | $43.24 | 2025 | |
| Alnylam Pharmaceuticals INC. | $41.05 | 2020-2023 | Oxlumo |
| Dendreon Pharmaceuticals LLC | $31.05 | 2024 | Provenge |
| Tolmar, INC. | $27.50 | 2023 | |
| Ferring Pharmaceuticals INC. | $23.27 | 2024 | |
| Endo Pharmaceuticals INC. | $22.60 | 2023 | Aveed, Xiaflex |
| Progenics Pharmaceuticals, INC. | $21.66 | 2025 | |
| Neotract INC. | $21.35 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $20.53 | 2022 | |
| Agiliti Surgical, INC. | $20.31 | 2022 | |
| Axonics, INC. | $17.30 | 2022 | |
| Convatec INC. | $16.33 | 2021 | |
| Ambu INC. | $15.20 | 2020 | |
| Olympus America INC. | $14.51 | 2019 | |
| Travere Therapeutics, INC. | $5.13 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.